In MLex, MBHB Partner Kevin Noonan discusses the implications of GSK and Moderna’s patent cross-licensing agreement, including how uncertainty surrounding a separate patent dispute involving Moderna and Arbutus may have provided an incentive to settle. Noonan also addresses the importance of mRNA delivery technology patents and what the agreement may signal about the companies’ willingness to resolve future disputes. Read the article.